What is the role of pharmacologic therapy in the treatment of the endocrine syndromes in McCune-Albright syndrome (MAS)?

Updated: Jan 05, 2021
  • Author: Gabriel I Uwaifo, MD; Chief Editor: George T Griffing, MD  more...
  • Print

In patients with MAS, other identified comorbidities that may be significantly affecting the bone density in a negative way must be identified and aggressively managed. Major morbidities and recommended treatments include the following:

  • Hypogonadism - Appropriate hormone replacement therapy

  • Hypophosphatemia with hyperphosphaturia - Aggressive oral phosphorus replacement

  • Hypophosphatemic rickets - Appropriate calcium supplementation, phosphate repletion, and calcitriol administration

  • Hyperparathyroidism (primary or secondary)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!